Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHK2375 (Entinostat) + Exemestane in Advanced Breast Cancer
NCT02623751Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Nov 2015
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of entinostat in breast cancer, sponsored by Kyowa Kirin. Primary endpoint: Number and percentage of subjects with treatment-emergent adverse events including dose-limiting toxicities and serious adverse events. Started Nov 2015; status: completed.
02
Drugs
entinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02623751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623751.